论文部分内容阅读
[目的]观察血必净联合乌司他丁辅助治疗感染性休克的临床疗效。[方法]将80例感染性休克患者,按随机数字表法,分为治疗组和对照组,每组40例。对照组采用常规治疗,治疗组在对照组治疗的基础上,给予乌司他丁10万U加生理盐水100mL、血必净注射液100mL加0.9%氯化钠注射液100mL静脉滴注,连用1周。治疗1周后进行疗效判定。[结果]两组BUN、AST、Cr、及ALT在治疗前均有升高表现(P>0.05),治疗后72h均降低,但与对照组比较,治疗组下降幅度显著,两组有统计学差异(P<0.05)。两组疗前乳酸水平和血清hs-CRP无明显差异(P>0.05),疗后72h均下降,治疗组幅度更为显著(P<0.05)。行72h治疗后,治疗组临床总有效率为95.00%,对照组为75.00%,治疗组优于对照组(P<0.05)。[结论]血必净联合乌司他丁治疗感染性休克具有较高安全性和有效性,显著改善了患者生活质量。
[Objective] To observe the clinical efficacy of Xuebijing combined with ulinastatin in the treatment of septic shock. [Methods] Eighty septic shock patients were divided into treatment group and control group according to random number table method, 40 cases in each group. The control group was treated with conventional therapy. The treatment group was given 100000 U of ulinastatin plus 100mL of saline, 100ml of Xuebijing injection and 100ml of 0.9% sodium chloride injection on the basis of the treatment of the control group, week. After 1 week of treatment efficacy judgment. [Results] The levels of BUN, AST, Cr and ALT increased in both groups before treatment (P> 0.05), and decreased at 72 hours after treatment. However, compared with the control group, the decrease rate of the treatment group was significant Difference (P <0.05). The levels of lactic acid and serum hs-CRP in the two groups had no significant difference (P> 0.05), but decreased at 72h after treatment. The amplitude of the treatment group was more significant (P <0.05). After 72h treatment, the total clinical effective rate was 95.00% in the treatment group and 75.00% in the control group, and the treatment group was superior to the control group (P <0.05). [Conclusion] Xuebijing combined with ulinastatin in treating septic shock has high safety and effectiveness, and significantly improves the quality of life of patients.